Tag:

Regeneron

Latest Headlines

Latest Headlines

Regeneron's would-be blockbuster completes the allergic circle with Phase II success

Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.

Regeneron touts its allergy drug as a blockbuster in waiting

While Eylea brings in the money and the cardio contender alirocumab grabs the headlines, Regeneron believes one of its less heralded pipeline treatments could eventually outgrow both, treating the underlying cause behind a handful of chronic diseases.

Eylea gets yet another approval, this one in Japan

The approvals, and the sales, just keep piling up for Eylea, the blockbuster that Bayer shares with developer Regeneron. Just weeks after getting an important nod in Europe, it has won approval in Japan, the world's third largest market, for use in myopic choroidal neovascularization.

Regeneron nabs FDA 'breakthrough' tag for new Eylea use in diabetics

Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.

It's megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and Regeneron's rival alirocumab. Despite some dramatic new data from the latter team--and a first-up filing with the FDA by Amgen--analysts figure on a dead heat once the drugs hit the market.

Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field?

When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and Regeneron's rival alirocumab. Despite some dramatic new data from the latter team--and a first-up filing with the FDA by Amgen--analysts figure on a dead heat once the drugs hit the market.

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.

Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power

Who's worried about the drug-pricing debate? Regeneron's CEO, for one

Are C-level execs really listening to the brouhaha over drug prices? With new drugs still rolling out in the U.S. at big premiums, one might think not. But if Regeneron chief Leonard Schleifer is speaking for his colleagues, then the answer is yes.

Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion

Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.